Browse Tag

Oral GLP-1

2 Articles

Scientific illustration of Ascletis’ ASC30 once-daily oral small-molecule GLP-1 receptor agonist, showing GLP-1 receptor binding, appetite and gastrointestinal effects, weight reduction and global Phase III clinical development.

Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30

By Xiaoxin Du

8 Min Read

Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…

Illustration of Innovent Biologics’ IBI3042, a once-weekly oral GLP-1 receptor agonist, showing oral absorption, GLP-1 receptor activation and potential effects on weight loss, blood glucose and appetite.

Innovent’s Once-Weekly Oral GLP-1 IBI3042 Gets NMPA IND Clearance for Obesity

By Henry Tseng

No Comments

6 Min Read

Innovent Biologics has received clearance from China’s National Medical Products Administration (NMPA) to begin clinical development of IBI3042, a potentially first-in-class once-weekly oral small-molecule GLP-1 receptor agonist, marking another…